Matt Abernethy - Zimmer Biomet CPA, Vice President Investor Relations

ZBH Stock  USD 131.98  0.63  0.48%   

President

Matt Abernethy is CPA, Vice President Investor Relations of Zimmer Biomet Holdings since 2017.
Age 37
Tenure 7 years
Address 345 East Main Street, Warsaw, IN, United States, 46580
Phone574 373 3333
Webhttps://www.zimmerbiomet.com

Zimmer Biomet Management Efficiency

The company has Return on Asset of 0.044 % which means that on every $100 spent on assets, it made $0.044 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0836 %, implying that it generated $0.0836 on every 100 dollars invested. Zimmer Biomet's management efficiency ratios could be used to measure how well Zimmer Biomet manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Capital Employed is estimated to decrease to 0.07. The current Return On Assets is estimated to decrease to 0.05. As of now, Zimmer Biomet's Asset Turnover is decreasing as compared to previous years.
The company has 6 B in debt with debt to equity (D/E) ratio of 0.48, which is OK given its current industry classification. Zimmer Biomet Holdings has a current ratio of 1.94, which is typical for the industry and considered as normal. Debt can assist Zimmer Biomet until it has trouble settling it off, either with new capital or with free cash flow. So, Zimmer Biomet's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Zimmer Biomet Holdings sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Zimmer to invest in growth at high rates of return. When we think about Zimmer Biomet's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Lisa UthgenanntLaboratory
57
Noelle EderCigna Corp
54
Marcel RocheGuardant Health
N/A
Sandra VaartLaboratory
64
Glenn EisenbergLaboratory
63
Matt PerlbergCigna Corp
N/A
MICHAEL TRIPLETTCigna Corp
59
Nicole JonesCigna Corp
53
Kristen LauriaCigna Corp
51
Michael StanleyMednax Inc
68
Karl WagnerMednax Inc
49
Lisa BacusCigna Corp
53
Dean MirabellaCigna Corp
N/A
John MurabitoCigna Corp
62
Dominic AndreanoMednax Inc
52
Edwin DetrickCigna Corp
N/A
C RichardsMednax Inc
50
Brian CaveneyLaboratory
47
Mark BoxerCigna Corp
59
John PepiaMednax Inc
61
Brain EvankoCigna Corp
40
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. Zimmer Biomet operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 19500 people. Zimmer Biomet Holdings (ZBH) is traded on New York Stock Exchange in USA. It is located in 345 East Main Street, Warsaw, IN, United States, 46580 and employs 18,000 people. Zimmer Biomet is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Zimmer Biomet Holdings Leadership Team

Elected by the shareholders, the Zimmer Biomet's board of directors comprises two types of representatives: Zimmer Biomet inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zimmer. The board's role is to monitor Zimmer Biomet's management team and ensure that shareholders' interests are well served. Zimmer Biomet's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zimmer Biomet's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sreelakshmi Kolli, Independent Director
Didier Deltort, President - Europe, Middle East and Africa
Carrie Nichol, Chief Accounting Officer, Vice President Controller
Arthur Higgins, Independent Director
Coleman Lannum, Senior Vice President - Investor Relations
Michael Michelson, Independent Director
Larry Glasscock, Independent Non-Executive Chairman of the Board
Nitin Goyal, Chief Science, Technology and Innovation Officer
Matt Abernethy, CPA, Vice President Investor Relations
Ellison Humphrey, Senior Vice President, Chief Transformation Officer
Daniel Florin, CFO, Senior Vice President
Robert Marshall, Vice President - Investor Relations, Treasurer
David Nolan, Group President of Biologics, Extremities, Sports Medicine, Surgical, Trauma, Foot and Ankle and Bone Healing
Joseph Cucolo, President Americas
Derek Davis, Chief Accounting Officer, Vice President, Controller
Ivan Tornos, Group President - Global Businesses and Americas
Cecil Pickett, Independent Director
Angela Main, Global VP
Aure Bruneau, Group President Spine, CMF, Thoracic and Surgery Assisting Technology
Jeffrey Rhodes, Director
Wilfred Zuilen, President - Europe, Middle East and Africa
Katarzyna MazurHofsaess, President Europe, Middle East and Africa
Suketu Upadhyay, Chief Financial Officer, Executive Vice President
Paul Bisaro, Independent Director
Zeeshan Tariq, Senior Officer
Christopher Begley, Lead Independent Director
Bryan Hanson, Chairman of the Board, President, Chief Executive Officer
Sang Yi, President Asia Pacific
Betsy Bernard, Independent Director
Keri Mattox, Senior Vice President - Investor Relations, Chief Communications Officer
Adam Johnson, Group President Spine, Dental, CMF and Thoracic
Maria Hilado, Independent Director
Rachel Ellingson, Senior Vice President Chief Strategy Officer, Executive Officer
Daniel Williamson, Group President Joint Reconstruction
Nitin MD, Technology Science
Chad Phipps, Senior Vice President, General Counsel, Secretary
Syed Jafry, Independent Director
Paul Stellato, Controller VP
David Dvorak, CEO and President and Director
Michael Farrell, Independent Director
Tony Collins, Chief Accounting Officer, Vice President Controller
Lori Winkler, Chief Human Resource Officer, Senior Vice President
Zachary CPA, Director Relations
Gail Boudreaux, Independent Director
Stuart Kleopfer, President Americas
Robert Hagemann, Independent Director
Robert Delps, President Americas

Zimmer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zimmer Biomet a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:
Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics.
Note that the Zimmer Biomet Holdings information on this page should be used as a complementary analysis to other Zimmer Biomet's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Complementary Tools for Zimmer Stock analysis

When running Zimmer Biomet's price analysis, check to measure Zimmer Biomet's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zimmer Biomet is operating at the current time. Most of Zimmer Biomet's value examination focuses on studying past and present price action to predict the probability of Zimmer Biomet's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zimmer Biomet's price. Additionally, you may evaluate how the addition of Zimmer Biomet to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Money Managers
Screen money managers from public funds and ETFs managed around the world
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Is Zimmer Biomet's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.16)
Dividend Share
0.96
Earnings Share
4.88
Revenue Per Share
35.43
Quarterly Revenue Growth
0.063
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.